BRD7116 is primarily utilized in the field of medical research, particularly in the study of cancer biology. It serves as a potent and selective inhibitor of BET bromodomain proteins, which play a critical role in regulating gene expression. By targeting these proteins, BRD7116 helps researchers investigate the mechanisms of transcriptional regulation in cancer cells, offering insights into potential therapeutic strategies. Its application extends to preclinical studies, where it is used to evaluate the efficacy of BET inhibition in halting tumor growth and proliferation. Additionally, BRD7116 is employed in biochemical assays to understand the interactions between BET proteins and chromatin, aiding in the development of novel cancer treatments.